Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

411 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Benralizumab for the Prevention of COPD Exacerbations.
Criner GJ, Celli BR, Brightling CE, Agusti A, Papi A, Singh D, Sin DD, Vogelmeier CF, Sciurba FC, Bafadhel M, Backer V, Kato M, Ramírez-Venegas A, Wei YF, Bjermer L, Shih VH, Jison M, O'Quinn S, Makulova N, Newbold P, Goldman M, Martin UJ; GALATHEA Study Investigators; TERRANOVA Study Investigators. Criner GJ, et al. Among authors: brightling ce. N Engl J Med. 2019 Sep 12;381(11):1023-1034. doi: 10.1056/NEJMoa1905248. Epub 2019 May 20. N Engl J Med. 2019. PMID: 31112385 Clinical Trial.
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study.
Menzies-Gow A, Wechsler ME, Brightling CE, Korn S, Corren J, Israel E, Chupp G, Bednarczyk A, Ponnarambil S, Caveney S, Almqvist G, Gołąbek M, Simonsson L, Lawson K, Bowen K, Colice G; DESTINATION study investigators. Menzies-Gow A, et al. Among authors: brightling ce. Lancet Respir Med. 2023 May;11(5):425-438. doi: 10.1016/S2213-2600(22)00492-1. Epub 2023 Jan 23. Lancet Respir Med. 2023. PMID: 36702146 Clinical Trial.
Simvastatin in Critically Ill Patients with Covid-19.
REMAP-CAP Investigators; Hills TE, Lorenzi E, Berry LR, Shyamsundar M, Al-Beidh F, Annane D, Arabi Y, Aryal D, Au C, Beane A, Bhimani Z, Bonten M, Bradbury CA, Brunkhorst FM, Burrell A, Buxton M, Calfee CS, Cecconi M, Cheng AC, Cove ME, Detry MA, Estcourt LJ, Fitzgerald M, Goligher EC, Goossens H, Green C, Haniffa R, Harrison DA, Hashmi M, Higgins AM, Horvat C, Huang DT, Ichihara N, Jayakumar D, Kruger PS, Lamontagne F, Lampro L, Lawler PR, Marshall JC, Mason AJ, McGlothlin A, McGuinness S, McQuilten ZK, McVerry BJ, Mouncey PR, Murthy S, Neal MD, Nichol AD, O'Kane CM, Parke RL, Parker JC, Rabindrarajan E, Reyes LF, Rowan KM, Saito H, Santos M, Saunders CT, Seymour CW, Shankar-Hari M, Sinha P, Thompson BT, Turgeon AF, Turner AM, van de Veerdonk F, Weis S, Young IS, Zarychanski R, Lewis RJ, McArthur CJ, Angus DC, Berry SM, Derde LPG, Webb SA, Gordon AC, McAuley DF. REMAP-CAP Investigators, et al. N Engl J Med. 2023 Dec 21;389(25):2341-2354. doi: 10.1056/NEJMoa2309995. Epub 2023 Oct 25. N Engl J Med. 2023. PMID: 37888913 Free PMC article. Clinical Trial.
Development of a tool to detect small airways dysfunction in asthma clinical practice.
Kocks J, van der Molen T, Voorham J, Baldi S, van den Berge M, Brightling C, Fabbri LM, Kraft M, Nicolini G, Papi A, Rabe KF, Siddiqui S, Singh D, Vonk J, Leving M, Flokstra-de Blok B. Kocks J, et al. Eur Respir J. 2023 Mar 30;61(3):2200558. doi: 10.1183/13993003.00558-2022. Print 2023 Mar. Eur Respir J. 2023. PMID: 36517179 Free PMC article.
Airway remodelling in asthma and the epithelium: on the edge of a new era.
Varricchi G, Brightling CE, Grainge C, Lambrecht BN, Chanez P. Varricchi G, et al. Among authors: brightling ce. Eur Respir J. 2024 Apr 18;63(4):2301619. doi: 10.1183/13993003.01619-2023. Print 2024 Apr. Eur Respir J. 2024. PMID: 38609094 Free PMC article. Review.
Nebulised interferon-β1a (SNG001) in hospitalised COVID-19: SPRINTER phase III study.
Monk PD, Brookes JL, Tear VJ, Batten TN, Mankowski M, Adzic-Vukicevic T, Crooks MG, Dosanjh DPS, Kraft M, Brightling CE, Gabbay FJ, Holgate ST, Djukanovic R, Wilkinson TMA. Monk PD, et al. Among authors: brightling ce. ERJ Open Res. 2023 Mar 27;9(2):00605-2022. doi: 10.1183/23120541.00605-2022. eCollection 2023 Mar. ERJ Open Res. 2023. PMID: 36994453 Free PMC article.
Airway dysbiosis accelerates lung function decline in chronic obstructive pulmonary disease.
Liang W, Yang Y, Gong S, Wei M, Ma Y, Feng R, Gao J, Liu X, Tu F, Ma W, Yi X, Liang Z, Wang F, Wang L, Chen D, Shu W, Miller BE, Tal-Singer R, Donaldson GC, Wedzicha JA, Singh D, Wilkinson TMA, Brightling CE, Chen R, Zhong N, Wang Z. Liang W, et al. Among authors: brightling ce. Cell Host Microbe. 2023 Jun 14;31(6):1054-1070.e9. doi: 10.1016/j.chom.2023.04.018. Epub 2023 May 18. Cell Host Microbe. 2023. PMID: 37207649 Free article.
Long-term effect of dupilumab on prevention of lung function decline in patients with uncontrolled moderate-to-severe asthma: ATLAS trial design.
De Prado Gomez L, Pavord I, Busse W, Brightling CE, Wechsler ME, Rabe KF, Zhang M, Xing J, Jacob-Nara JA, Rowe PJ. De Prado Gomez L, et al. Among authors: brightling ce. ERJ Open Res. 2023 Mar 6;9(2):00417-2022. doi: 10.1183/23120541.00417-2022. eCollection 2023 Mar. ERJ Open Res. 2023. PMID: 36891077 Free PMC article.
Biomarkers and clinical outcomes after tezepelumab cessation: Extended follow-up from the 2-year DESTINATION study.
Brightling CE, Caminati M, Llanos JP, Caveney S, Kotalik A, Griffiths JM, Lundahl A, Israel E, Pavord ID, Wechsler ME, Porsbjerg C, Corren J, Gołąbek M, Martin N, Ponnarambil S. Brightling CE, et al. Ann Allergy Asthma Immunol. 2024 Sep;133(3):310-317.e4. doi: 10.1016/j.anai.2024.04.031. Epub 2024 Apr 30. Ann Allergy Asthma Immunol. 2024. PMID: 38697286 Free article. Clinical Trial.
411 results